Abu Syed Md Anisuzzaman | Oncology | Research Excellence Award

Published on by Global Scholar Awards

Dr. Abu Syed Md Anisuzzaman | Oncology | Research Excellence Award

Laboratory Molecular Technologist | Florida Cancer Specialists & Research Institute | United States

Dr. Abu Syed Md Anisuzzaman is a researcher affiliated with the University of Rajshahi, Bangladesh, specializing in pharmacology, molecular biology, and biomedical sciences. With 21 publications, 368 citations, and an h-index of 12, he has established a strong academic profile in cellular signaling, cancer biology, and therapeutic research. His work includes studies on apoptosis in cancer cells, oxidative stress, and intestinal epithelial function, contributing to advancements in drug discovery and disease mechanisms. Actively collaborating with international researchers, his research holds significant societal impact by supporting the development of novel therapeutic strategies, improving understanding of disease pathways, and advancing biomedical and pharmaceutical sciences globally.

Citation Metrics (Scopus)

368
275
180
90
0

Citations

368

Documents

21

h-index

12

Citations

Documents

h-index

View Scopus Profile
 View Google Scholar Profile
 View ORCID Profile

Featured Publications

Daulet Berikbol | Oncology | Scientific Advancement Achievement Award

Published on by Global Scholar Awards

Dr. Daulet Berikbol | Oncology | Scientific Advancement Achievement Award

UMIT International Oncology Center for Tomotherapy, LLP | Kazakhstan

Dr. Berikbol Daulet is a medical researcher at the UMIT International Oncological Center of Tomotherapy, Astana, Kazakhstan, with expertise in radiation oncology, tomotherapy, and advanced cancer treatment strategies. His research focuses on integrating precision radiotherapy with immunological and cellular therapies to improve outcomes in complex and advanced-stage cancers. He has authored 4 peer-reviewed publications, received 2 citations, and holds an h-index of 1, reflecting focused and emerging contributions to clinical oncology. Dr. Daulet actively engages in multidisciplinary clinical and translational research, contributing to collaborative studies that bridge radiotherapy and immunotherapy. His recent open-access case report on combined tomotherapy and autologous peripheral-blood–derived lymphocyte infusion for stage IIIa lung cancer highlights innovative, patient-centered treatment approaches, particularly for elderly patients. Through applied clinical research, he supports evidence-based oncology practice, advances modern cancer treatment technologies, and contributes to improved patient outcomes and broader societal benefit in healthcare.

Citation Metrics (Scopus)

4
3
2
1
0

Citations

2

Documents

4

h-index

1

Citations

Documents

h-index

View Scopus Profile View ORCID Profile

Featured Publications

Sara Mogedano Cruz | Oncology | Young Scientist Award

Published on by Global Scholar Awards

Mrs. Sara Mogedano Cruz | Oncology | Young Scientist Award

Universidad Europea de Madrid | Spain

Sara Mogedano-Cruz is a developing scholar in the field of biomedical and clinical sciences, affiliated with the Universidad Europea de Madrid in Villaviciosa de Odón, Spain, where she focuses on anatomical variability, anthropometric modeling, and evidence-based approaches to improving procedural safety. Her research emphasizes the integration of quantitative anatomical assessment into clinical workflows to enhance precision, reduce risk, and support safer invasive procedures. She has contributed to interdisciplinary studies that bridge anatomy, physiotherapy, clinical biomechanics, and medical engineering, strengthening the translation of scientific evidence into patient-centered practice. Her notable work includes the publication Predicting Median Nerve Depth from Anthropometric Features: A Tool for Safer Invasive Procedures, which examines how anthropometric predictors can guide clinicians in estimating nerve depth more accurately. Additionally, she co-authored the case report Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy, reflecting her engagement with clinically meaningful interventions and her involvement in research that intersects neuromuscular assessment and oncology-related neuropathy. With five indexed documents and collaborations with national and international researchers, her scholarship is gaining visibility, supported by a growing citation record that underscores the relevance of her work to emerging clinical methodologies. Through her commitment to methodological rigor and multidisciplinary inquiry, she aims to advance innovations that connect anatomical science, clinical decision-making, and technological development for improved patient outcomes and broader societal benefit. Sara Mogedano-Cruz’s academic influence and research productivity are reflected in her metrics: 18 citations, 5 documents, and an h-index of 1.

Profiles: Scopus | ORCID

Featured Publication

1. Mogedano-Cruz, S., González-de-la-Flor, Á., Rodríguez-Anadón, C., Bohn, L., Villafañe, J., & Romero-Morales, C. (2025). Predicting median nerve depth from anthropometric features: A tool for safer invasive procedures. PLoS ONE, 20(8), e0330383. (Cited by: 1).

Boya Guan | Medical Oncology | Best Researcher Award

Published on by Global Scholar Awards

Prof. Boya Guan | Medical Oncology | Best Researcher Award

Pharmacist-in-charge​ at Tianjin Hospital | China

Boya Guan is a dedicated researcher and clinical pharmacist whose work bridges pharmacology, toxicology, and pharmaceutical sciences with a primary focus on osteosarcoma and bone cancer therapeutics. Over the course of her professional career, she has contributed significantly to oncology research by exploring drug mechanisms, drug resistance pathways, biomarker discovery, and clinical pharmacology applications. Her studies on triptolide-mediated ferroptosis and therapeutic strategies for overcoming drug resistance highlight her innovative approach to cancer research. Alongside her academic and clinical roles, she has been actively involved in translational projects that connect laboratory findings with patient care, ensuring that scientific discoveries lead to tangible clinical benefits. She has published in SCI-indexed journals, contributed to book chapters, and presented at national and international conferences, reflecting both the quality and impact of her work. With a strong commitment to research, innovation, and knowledge dissemination, she continues to shape advancements in oncology and pharmaceutical sciences.

Professional Profiles

Scopus Profile | ORCID Profile 

Education

Boya Guan has built a solid academic foundation that supports her extensive contributions to pharmaceutical research and clinical practice. She first pursued a degree in Pharmacy at Tianjin Medical University, where she developed a deep understanding of pharmacological principles and clinical applications. To expand her academic and professional horizons, she later completed a master’s program in Project and Operations Management at Southern New Hampshire University in the United States, equipping her with essential skills in management, leadership, and Six Sigma quality processes. This unique blend of pharmaceutical knowledge and operations management enabled her to approach research with a strategic and interdisciplinary perspective. She is currently advancing her expertise further by pursuing a master’s program in Pharmaceutical Analysis at Tianjin Medical University, focusing on advanced analytical methods and their role in clinical pharmacology. Her continuous academic development reflects her commitment to lifelong learning, professional growth, and scientific excellence in pharmaceutical sciences.

Experience

With over fourteen years of professional experience, Boya Guan has established herself as a highly skilled clinical pharmacist and researcher at Tianjin Hospital. In her role, she has been actively engaged in oncology-related pharmaceutical care, focusing on the mechanisms and efficacy of anticancer drugs while contributing to translational medicine initiatives. She has participated in significant clinical pharmacist training programs under the Tianjin Shortage Talent Program, where she deepened her expertise in oncology pharmacology and inpatient pharmaceutical care. Her experience is not limited to direct patient support; she has also been actively involved in clinical research, collaborating on projects that evaluate novel therapeutics such as denosumab for bone metastases and AI-based diagnostic tools. Beyond hospital-based responsibilities, she has presented her findings at conferences, published in peer-reviewed journals, and contributed book chapters, thereby extending her influence to both clinical and academic communities. Her experience reflects a balanced integration of research, practice, and innovation.

Research Interest

Boya Guan’s research interests lie at the intersection of oncology pharmacology, drug resistance mechanisms, and biomarker discovery, with a special focus on osteosarcoma therapeutics. She is particularly interested in investigating how targeted therapies and novel molecular pathways can overcome resistance to conventional drugs, thereby improving treatment outcomes for cancer patients. Her notable work includes exploring the role of triptolide in reversing cisplatin resistance through ferroptosis and lysosomal regulation, offering a promising therapeutic strategy. In addition to oncology, she is deeply engaged in analytical chemistry, employing dual-channel metabolomics and lipidomics approaches to identify biomarkers for diseases such as diabetes, thus contributing to early detection and precision medicine. She has also conducted systematic reviews and meta-analyses on VEGFR-TKIs in osteosarcoma, providing valuable evidence for clinical practice. Through her interdisciplinary approach, she aims to bridge pharmacology, translational research, and clinical application, ensuring her research has a meaningful and lasting impact on patient care.

Awards and Honors

Throughout her career, Boya Guan has earned recognition for her contributions to clinical pharmacy, research excellence, and innovative approaches to oncology therapeutics. She has been selected for prestigious programs such as the Tianjin Shortage Talent Program, which provided advanced clinical pharmacist training in oncology and inpatient care, underscoring her recognition as a promising specialist in pharmaceutical sciences. Her scientific contributions, including SCI-indexed journal publications, systematic reviews, and a book chapter on spinal metastases surgery, have also positioned her as a valuable contributor to academic and clinical communities. In addition to her professional achievements, she has been invited to present at multiple national and international conferences, where her research has been well received and acknowledged by peers. These honors reflect not only her strong academic and research background but also her potential to influence future directions in oncology and pharmaceutical research. Her growing recognition continues to strengthen her professional standing globally.

Research Skills

Boya Guan possesses a diverse range of research skills that combine laboratory expertise, clinical insight, and analytical methodologies. She is proficient in oncology pharmacology research, with specialized experience in studying drug resistance pathways, including ferroptosis-related mechanisms in osteosarcoma. Her analytical chemistry expertise includes metabolomics and lipidomics approaches for biomarker discovery, enabling her to contribute to the development of diagnostic and prognostic tools for complex diseases. She is skilled in conducting systematic reviews, meta-analyses, and clinical evaluations, ensuring evidence-based contributions to both research and practice. Additionally, she has demonstrated competence in designing and managing multidisciplinary research projects, including collaborations on AI-based diagnostic systems and drug efficacy studies. Her ability to translate laboratory findings into clinical strategies highlights her strength in bridging basic science with medical application. Coupled with strong writing, publication, and presentation skills, she is well-equipped to advance knowledge dissemination and foster innovation in oncology and pharmaceutical sciences.

Publication Top Notes

Title: Development of a dual-channel analytical approach for diabetic biomarker discovery in blood via integrative metabolomics and lipidomics
Year: 2025

Conclusion

Overall, Boya Guan is a highly deserving candidate for the Best Researcher Award. Her impactful contributions to osteosarcoma research, oncology pharmacology, biomarker discovery, and clinical drug evaluation showcase her ability to merge scientific innovation with real-world medical application. Her strong academic background, leadership in research, and commitment to improving cancer therapeutics reflect excellence in both scholarship and societal impact. With her continued focus on translational medicine and international collaborations, she holds significant potential to emerge as a global leader in oncology and pharmaceutical sciences.

Luca Roncati | Breast Cancer | Best Researcher Award

Published on by Global Scholar Awards

Prof. Dr. Luca Roncati | Breast Cancer | Best Researcher Award

Professor, Department of Life Sciences, Health, and Health Care Professions, School of Medicine and Surgery, Link Campus University, Rome, Italy,Italy

Dr. Luca Roncati is a highly accomplished researcher whose career is marked by pioneering studies in multiple areas of pathology and oncology. His work on gynecologic oncology, nanopathology, and COVID-19 has had a significant impact on medical science, particularly in improving diagnostic techniques and therapeutic options for patients. He has demonstrated leadership not only through his research but also in his educational roles and editorial leadership in major scientific journals. His innovative contributions to cancer treatment, as seen in his patents and research, position him as a key figure in medical advancement. The Roncati-Manenti Triad and his description of T rex lymphoma further illustrate his ability to make groundbreaking discoveries in pathology. Additionally, his COVID-19 research was instrumental during the pandemic and continues to influence the medical community today.

Professional Profile

Education🎓

Dr. Luca Roncati holds an extensive academic background in medicine and pathology. He graduated in Medicine and Surgery, followed by specialization in Pathological Anatomy, Oncology, Senology, Clinical Pathology, and Forensic Medicine. He has also achieved National Scientific Habilitation for roles in Obstetrical-Gynecological Sciences and Technical Sciences of Laboratory Medicine, solidifying his expertise in clinical, organizational, epidemiological, and social aspects of healthcare. Dr. Roncati’s qualifications have been recognized on an international level, particularly within the academic and healthcare sectors.

Professional Experience📝

Dr. Roncati is currently a Full-Time Professor of Pathology at Link Campus University in Rome, Italy, where he imparts knowledge in the fields of medical pathology and oncology. In addition, he holds a position as a Medical Executive at the University Hospital of Modena, where he works with interdisciplinary teams to deliver clinical care. He is also an Adjunct Professor at the University of Modena and Reggio Emilia. Throughout his career, he has served as an academic editor and reviewer for several prestigious journals, contributing to advancing knowledge in the fields of Oncology, Pathology, and Gynecology.

Research Interest🔎

Senology and Gynecologic Oncology: He is known for his in-depth research into the pathophysiology of breast cancer and gynecological malignancies.Pediatric Pathology: His work in pediatric oncology has provided critical insights into childhood cancers.Hematopathology and Soft Tissue Tumors: Dr. Roncati has contributed significantly to understanding hematologic conditions and soft tissue tumors.Nanopathology: He is recognized as a leading researcher in nanopathology, particularly in the integration of nanotechnology in medical diagnostics and treatment.COVID-19: Dr. Roncati was among the pioneering researchers investigating the impacts and pathology of COVID-19, publishing influential papers that have shaped the understanding of the disease.Forensic Pathology: As a forensic expert, he has contributed to advancements in medico-legal investigations.

Awards and Recognition🏆

International Research Recognition: His pioneering work in COVID-19 research and nanopathology has been widely cited. Academic Excellence: He has been selected as a distinguished academic by Times Higher Education and has been recognized for his contributions to the world university rankings. Innovative Cancer Research: He holds patents for anti-cancer therapies, cementing his place as a leader in cancer research.

Skills and Expertise🔬

Medical Research: Extensive experience in clinical and laboratory-based research, particularly in oncology and pathology.Patent Innovation: He is an inventor of anti-cancer therapies and holds international patents.Forensic Pathology: Expertise in medico-legal investigations, including autopsies and criminal pathology.Academic Leadership: Dr. Roncati has played a pivotal role in mentoring the next generation of pathologists and scientists.Nanotechnology in Medicine: Pioneering work in the application of nanotechnology to pathology and cancer research.

Conclusion💡

Dr. Luca Roncati exemplifies the qualities of a Best Researcher Award nominee. His extensive academic background, coupled with his pioneering research in oncology, nanopathology, and COVID-19, makes him a standout candidate. His innovation in anti-cancer therapies, along with his dedication to advancing scientific knowledge, demonstrates his remarkable ability to improve both patient care and medical practice. While there are areas for potential improvement, such as increased public engagement and cross-disciplinary collaboration, his current body of work is substantial and continues to shape the landscape of modern medicine. Dr. Roncati’s leadership, influence, and groundbreaking discoveries solidify his status as one of the leading medical researchers of our time. He is undoubtedly a deserving candidate for the Best Researcher Award.

Publications Top Noted✍

1. Title: Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal

  • Author: Roncati, Luca
    Year: Not specified
    Citations: 0

2. Title: Ozone–Oxygen Therapy to Prevent HPV-Related Cancers of the Lower Gynecological Tract in Infected Patients: The Rationale for Further Developments

  • Author: Roncati, Luca
    Journal: Cancers
    Year: 2025
    Citations: 0

3. Title: COVID-19 and upper limb compression neuropathies: a review

  • Authors: Marra, Caterina; de Maria, Federico; Boccaletti, Martina; Roncati, Luca; Adani, Roberto
    Year: Not specified
    Citations: 0

4. Title: Ultramicronized Palmitoylethanolamide and Luteolin: Drug Candidates in Post-COVID-19 Critical Illness Neuropathy and Positioning-Related Peripheral Nerve Injury of the Upper Extremity

  • Authors: Roncati, Luca; Marra, Caterina; Gravina, Davide; Della Rosa, Norman; Adani, Roberto
    Journal: Journal of Hand and Microsurgery
    Year: 2024
    Citations: 3

 

5. Title: A Real-World Nationwide Study on COVID-19 Trend in Italy during the Autumn–Winter Season of 2020 and 2021 Integrated with a Retrospective Analysis of the Mortality Burden per Year

  • Authors: Manenti, Antonio; Roncati, Luca; Sorrentino, Lorena; Gelmini, Roberta; Coppi, Francesca
    Journal: Vascular
    Year: 2024
    Citations: 0

6. Title: Thoracic aortic pseudoaneurysm: Inside its pathophysiology

  • Authors: Manenti, Antonio; Roncati, Luca; Sorrentino, Lorena; Gelmini, Roberta; Coppi, Francesca
    Journal: Vascular
    Year: 2024
    Citations: 0

7. Title: Editorial: Endocrine disruptors and diseases of brain and mind: past and prelude

  • Authors: Johri, Ashu; Roncati, Luca; Lizcano, Fernando
    Year: Not specified
    Citations: 1

8. Title: Reply to: Letter on the Recent Paper “Vascular ‘Long COVID’: A New Vessel Disease?”

  • Authors: Johri, Ashu; Roncati, Luca; Lizcano, Fernando
    Year: Not specified
    Citations: 1

9. Title: Vascular “Long COVID”: A New Vessel Disease?

  • Authors: Zanini, Giada; Selleri, Valentina; Roncati, Luca; Pinti, Marcello; Mattioli, Anna Vittoria
    Year: Not specified
    Citations: 37

10. Title: Trends in the COVID-19 Pandemic in Italy during the Summers of 2020, 2021 and 2022: A Real-World Nationwide Study

  • Authors: Roncati, Luca; Bartolacelli, Giulia; Galeazzi, Carlo; Caramaschi, Stefania
    Journal: Pathogens
    Year: 2023
    Citations: 3

William Skelton | Medical Oncology | Best Researcher Award

Published on by Global Scholar Awards

Dr. William Skelton | Medical Oncology | Best Researcher Award

Assistant Professor of Medicine at University of Virginia Comprehensive Cancer Center, United States

Dr. William Paul Skelton IV is an Assistant Professor of Medicine at the University of Virginia School of Medicine, specializing in Hematology and Oncology. With extensive training from prestigious institutions like Moffitt Cancer Center and the University of Florida, Dr. Skelton is a dedicated clinician and researcher in Genitourinary Oncology. His career is marked by numerous awards, including recognition for excellence in patient care and teaching. Dr. Skelton is committed to advancing cancer treatment through research and has a notable record of impactful publications and presentations in the field. His professional contributions extend to mentoring and serving on various academic committees.

Publication Profile

Education

Dr. William Paul Skelton IV completed his Hematology/Oncology Fellowship at Moffitt Cancer Center, University of South Florida, followed by a Chief Medical Residency at the University of Florida. He earned his Internal Medicine Residency from the same institution and graduated with honors in research from the University of Florida College of Medicine. Dr. Skelton holds a Magna Cum Laude degree in Chemistry from Duke University and a high school diploma with exceptional achievements from King International Baccalaureate High School.

Experience

Dr. Skelton’s professional journey includes his current role as an Assistant Professor of Medicine at the University of Virginia School of Medicine. Previously, he served as a Hematology/Oncology Fellow at Moffitt Cancer Center and as a Chief Medical Resident during his Internal Medicine Residency at the University of Florida. His clinical expertise encompasses Genitourinary Oncology, and he has contributed significantly to medical education through precepting and mentoring medical students, residents, and fellows.

Awards and Honors

Dr. Skelton has received several prestigious awards, including the Moffitt Cancer Center SPOTTED in FellowSHIP patient care Recognition Award in both 2020 and 2021. He was honored with the Florida ACP Chief Resident Award and the UF Senior Resident Medical Student Teaching Award. Additional accolades include the Craig S. Kitchens Outstanding Senior Medicine Resident Award and selection into the Alpha Omega Alpha Honor Society. His academic honors also include Phi Beta Kappa and the Merck Index Award.

Research Focus

Dr. Skelton’s research primarily focuses on Genitourinary Oncology, particularly the therapeutic advancements and molecular mechanisms underlying renal and bladder cancers. His work includes investigating predictive tools for advanced renal cancer and exploring the impact of systemic therapies on cancer progression. Dr. Skelton’s research is aimed at improving patient outcomes through innovative treatment strategies and clinical trials.

Publications Top Notes

  • Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
    • Authors: Skelton, W.P., Masur, J., Thomas, J., Jain, R.K., Sonpavde, G.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 💊💉🩺
  • Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus
    • Authors: Ali, S., Fortune, K., Masur, J., Dreicer, R., Skelton, W.P.
    • Journal: Clinical Genitourinary Cancer
    • Year: 2024
    • Citations: 0 🩸👨‍⚕️🧬
  • Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer
    • Authors: Altshuler, E., Franke, A.J., Skelton, W.P., Dai, Y., George, T.J.
    • Journal: Clinical Colorectal Cancer
    • Year: 2023
    • Citations: 2 🧬🔬
  • Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
    • Authors: Zhang, Y., Kumar, P., Adashek, J.J., Manley, B.J., Spiess, P.E.
    • Journal: Cells
    • Year: 2022
    • Citations: 6 🧫🔬💊
  • FGFR2/3 Genomic Alterations and Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
    • Authors: Adib, E., El-Zarif, T., Jain, R.K., Choueiri, T.K., Sonpavde, G.P.
    • Journal: BJUI Compass
    • Year: 2022
    • Citations: 6 🧬💉🧪
  • Clinical Cases Debate: Neoadjuvant Versus Adjuvant Immunotherapy in Localized Renal Cell Carcinoma (RCC)
    • Authors: Skelton, W.P., Dahmen, A., Chatwal, M., Chahoud, J., Spiess, P.E.
    • Book Chapter: Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers
    • Year: 2022
    • Citations: 0 📖🦠💉
  • Optimal Pathological Response After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Results from a Global, Multicentre Collaboration
    • Authors: Ravi, P., Pond, G.R., Diamantopoulos, L.N., Grivas, P., Sonpavde, G.P.
    • Journal: BJU International
    • Year: 2021
    • Citations: 13 🧬🌍
  • Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients
    • Authors: Starr, J.S., Skelton, W.P., Rahmanian, K.P., George, T.J., Moseley, R.E.
    • Journal: Journal of Palliative Care
    • Year: 2021
    • Citations: 0 📊🩺📋
  • A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy
    • Authors: Franke, A.J., Skelton, W.P., George, T.J., Iqbal, A.
    • Journal: Clinical Colorectal Cancer
    • Year: 2021
    • Citations: 4 🧪📊
  • Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
    • Authors: Adashek, J.J., Zhang, Y., Skelton, W.P., Manley, B., Spiess, P.E.
    • Journal: Frontiers in Oncology
    • Year: 2021
    • Citations: 5 🧬🩺💉